{"id":"W4379282903","doi":"10.1200/jco.2023.41.16_suppl.4516","title":"Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Avelumab; Medicine; Discontinuation; Internal medicine; Metastatic Urothelial Carcinoma; Adverse effect; Oncology; Surgery; Bladder cancer; Urothelial carcinoma; Immunotherapy; Nivolumab; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002653767,0.0003435937,0.0008118257,0.0001795927,0.0002630286,0.001142102,0.0004239627,0.0005957707,0.00177462],"category_scores_gemma":[0.001864173,0.0002357363,0.0009499051,0.0002769135,0.0004177594,0.000677838,0.0003506242,0.001402945,0.0003041536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007571616,"about_ca_system_score_gemma":0.0006575835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003486128,"about_ca_topic_score_gemma":0.001124141,"domain_scores_codex":[0.9991508,0.0005502395,0.00004252732,0.00009887021,0.00006758283,0.00009007036],"domain_scores_gemma":[0.9988341,0.000229321,0.0004888697,0.0001086702,0.00004345124,0.000295637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7071703,0.01001395,0.07270962,0.0016514,0.004093145,0.0003002521,0.0003647805,0.003023842,0.02233125,0.0005054252,0.005799414,0.1720367],"study_design_scores_gemma":[0.3339361,0.3911515,0.2369002,0.0003702675,0.004800003,0.001903392,0.0002214342,0.005404164,0.009254863,0.001184392,0.014778,0.00009571626],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934019,0.004119515,0.0002537613,0.0002567196,0.0000389754,0.0002181063,0.0005841609,0.00002814775,0.001098627],"genre_scores_gemma":[0.9969684,0.0007763608,0.0002819811,0.0002048516,0.00004656583,0.0002324505,0.0008308957,0.000007570121,0.0006508518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002653767,"threshold_uncertainty_score":0.01403463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1404692180137173,"score_gpt":0.4619004423937132,"score_spread":0.3214312243799958,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}